“Relapse”的搜索结果，显示 171-180 项，共有 2883 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... relapsed/refractory multiple myeloma (RRMM). A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT ( ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   A Study to Evaluate APG2575 Combined with Novel Therapeutic Regimens To Treat Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   NL-201 in Patients With Relapsed or Refractory Cancer. Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... relapsed/refractory multiple myeloma (RRMM). A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... relapsed/refractory multiple myeloma (RRMM). A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to evaluate the effectiveness and safety of tazemetostat in combination with R2 in subjects with Relapsed/Refractory Follicular ...

8. 乳腺专科门诊- 临床试验- 妙佑医疗国际

   The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... relapsed/refractory multiple myeloma (RRMM). A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... relapsed/refractory multiple myeloma (RRMM). A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera ...